ALTSTATION.IO

Mettler-Toledo International Inc. (MTD) Stock Analysis

By Nova Skye | AltStation.io | Updated September 06, 2026

Price

$1353.40

Change

-0.21%

Market Cap

$27.12B

Avg Volume

190.9K

Company Overview

Mettler-Toledo International Inc. builds high-end precision instruments and software for laboratories, factories, and commercial retailers. Headquartered in Greifensee, Switzerland, the company operates in the Healthcare sector under the Diagnostics & Research industry. Their catalog spans laboratory balances, titrators, pipetting systems, and industrial inspection tools like metal detectors and checkweighers, supported by their proprietary LabX software platform. Their customer base covers pharmaceutical corporations, biotech startups, chemical producers, food processors, and academic research labs across five regional operating segments.

Mettler-Toledo is the undisputed market leader in precision weighing, controlling an estimated 25% to 30% of the global laboratory balances market. Their primary edge comes from proprietary sensor technology and the sticky LabX ecosystem, which embeds their hardware directly into strict pharmaceutical compliance workflows. Key rivals like Sartorius AG hold roughly 15% to 20% of the market, while firms like A&D Company and Thermo Fisher Scientific compete on specific instrument tiers. This dominant positioning gives the company clear pricing power, though heavy reliance on cyclical industrial demand and Chinese research spending leaves them exposed to regional capital expenditure slowdowns.

Financially, Mettler-Toledo is back in expansion mode, generating approximately $3.87 billion in 2024 revenue and climbing toward $4.03 billion in 2025 after 2023 shipping bottlenecks capped sales at $3.79 billion. The company is actively prioritizing automated workflows, expanding AI-driven fresh-goods recognition in retail and real-time process analytics for biopharma manufacturing. Instead of pursuing dilutive pivots, the business is doubling down on high-margin software integration and automated inspection to maximize revenue per customer. For investors, this is a premium compounder running a defensive playbook, where future upside depends directly on a sustained recovery in global laboratory research budgets.

Key Financials

Market Cap

$27.12B

Revenue

$4.13B

EBITDA

$1.28B

Gross Margin

60.3%

Profit Margin

21.9%

Revenue Growth

4.5%

Total Cash

$51.38M

Total Debt

$2.14B

Free Cash Flow

$693.59M

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

30.80

Forward P/E

26.17

Beta

1.22

52-Week High

$1525.17

52-Week Low

$1023.05

EPS

$43.94

50-Day Avg

$1358.56

200-Day Avg

$1319.69

Price/Book

2114.69

Technical Analysis

MTD trades at $1,353.40, placing it 64% of the way from its 52-week low of $1,023.05 to its $1,525.17 high. The stock is 11.80% below that high but remains 31.50% above the low. Price is 4.05% below its 20-day moving average of $1,401.98, confirming weak near-term momentum. MTD has fallen 3.81% over five trading days and 5.89% over 20 trading days. Near-term support is $1,336.29, while $1,445.00 is the resistance level buyers need to clear.

Recent News and Developments

Rothschild Redburn starts MTD at Sell

Rothschild & Co Redburn initiated Mettler-Toledo coverage on September 2 with a Sell rating and a $1,200 price target. That target was 10.8% below MTD’s September 4 closing price of $1,345.26. Source: StockAnalysis

RBC starts MTD at Sector Perform

RBC Capital initiated coverage on September 1 with a Sector Perform rating and a $1,515 price target. RBC praised the company’s business quality but cited a mixed opportunity set and risks to its long-range plan. Source: Investing.com

Baird keeps Neutral rating and lifts target by $2

Baird raised its Mettler-Toledo price target to $1,460 from $1,458 on September 3. The firm kept its Neutral rating, making the two-dollar increase insignificant as a fresh bullish signal. Source: MarketScreener

Market Sentiment and Analyst Recommendations

Bull Case

Revenue is growing 4.5%, giving MTD a positive fundamental base despite the recent share-price weakness. RBC praised the company’s business quality when it initiated coverage on September 1. The consensus recommendation is buy across 12 analysts, with an average target of $1,472.75 versus the current $1,353.40 price. The highest analyst target is $1,600.00, showing that some analysts still see meaningful room above the current price. Argus also set a $1,514 target on September 2, which was about 11.6% above the $1,356.23 price listed in its report. The bull case is straightforward: revenue is growing, analyst sentiment is broadly positive, and the recent decline offers an entry below the consensus target.

Bear Case

A P/E ratio of 30.80 is expensive next to revenue growth of 4.5%. That valuation leaves little room for slower growth or execution problems. MTD has only $51.38 million in cash against $2.14 billion in total debt, creating a clear balance-sheet concern. The stock is already below its 20-day moving average, with five-day momentum at negative 3.81% and 20-day momentum at negative 5.89%. Rothschild Redburn’s September 2 Sell rating and $1,200 target show that the analyst outlook is far from unanimous. With published targets ranging from $1,200 to $1,600, the market has a wide disagreement over what MTD deserves to be worth.

What to Watch

The first threshold is $1,336.29, the 30-day low and nearest identified support level. A sustained move back above the $1,401.98 moving average would improve the short-term setup. Bulls then need a break above the $1,445.00 30-day high to show that momentum has genuinely reversed. Investors should track whether revenue growth holds above, matches, or falls below the current 4.5% rate because the 30.80 P/E demands continued progress. Cash of $51.38 million and debt of $2.14 billion also need close attention over the next quarter. Finally, watch whether new analyst work moves closer to Redburn’s $1,200 target, Baird’s $1,460 target, RBC’s $1,515 target, or the current $1,472.75 consensus.

Analyst Consensus

BUY

Based on 12 analyst opinions

Low Target

$1200.00

Mean Target

$1472.75

High Target

$1600.00

Earnings and Financial Data

Sector

Healthcare

Industry

Diagnostics & Research

Employees

16,600

Earnings & Dividends

Next Earnings

Nov 05, 2026

EPS (Trailing)

$43.94

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is MTD a good stock to buy?

MTD has a buy recommendation from 12 analysts and revenue growth of 4.5%, but it trades at a P/E of 30.80. Takeaway: the data supports buying only if you accept a premium valuation.

What is MTD’s analyst price target?

The average analyst target is $1,472.75, with estimates ranging from $1,200.00 to $1,600.00. Takeaway: analysts see potential above $1,353.40, but the target range shows substantial disagreement.

Is MTD stock near its 52-week high?

MTD is 11.80% below its $1,525.17 high and sits 64% of the way through its 52-week range. Takeaway: the stock is in the upper half of its range but is not close to a breakout.

What are MTD’s support and resistance levels?

Near-term support is $1,336.29, and near-term resistance is $1,445.00. Takeaway: those are the key thresholds for the current setup.

Does MTD pay a dividend?

The provided data does not include dividend information. Takeaway: no dividend conclusion can be made from the available figures.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated September 06, 2026.